# AKBA — Akebia Therapeutics Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** AKBA  
**Sources:** 20  
**Published:** 2026-10-04  
**Canonical:** https://app.k3vl4r.com/research/deep-research-akba-akebia-therapeutics-inc-catalysts-narrative-risks-5960

---

## Overview / Price Context (as of early October 2026)

Akebia Therapeutics (Nasdaq: AKBA) is a Cambridge/Waltham, MA–based fully integrated renal biopharmaceutical company with two FDA-approved products, Vafseo (vadadustat) and Auryxia (ferric citrate) [[13]](https://stockanalysis.com/stocks/akba/transcripts/662071-q2-2026/), [[21]](https://akebia.com/), [[23]](https://akebia.com/about/). It is a small-cap name (roughly $255M market cap as of Oct 1, 2026 on file) with a share price that has collapsed: the stock hit $1.29 on the Q2 reporting day (Aug 5) but closed around $0.86 on Oct 2, 2026, versus ~$3.72 a year earlier [[7]](https://www.marketbeat.com/earnings/reports/2026-8-5-akebia-therapeutics-inc-stock/), [[11]](https://finance.yahoo.com/healthcare/articles/akebia-therapeutics-q2-earnings-snapshot-210409276.html). That low-price environment is material to the dilution and financing risk profile below.

## Recent Catalysts (July–October 2026)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-akba-akebia-therapeutics-inc-catalysts-narrative-risks-5960 (free to sign up)._
